Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients With Severe COVID-19
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs CAP-1002 (Primary)
- Indications COVID 2019 infections; Respiratory tract infections
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Capricor
- 07 Oct 2020 Status changed from recruiting to completed.
- 29 Apr 2020 Results (n=6) presented in the Capricor Therapeutics media release.
- 29 Apr 2020 According to a Capricor Therapeutics media release, the U.S. Food and Drug Administration (FDA) approved the Company's expanded access protocol to treat up to 20 additional COVID-19 patients. Data (n=6) from this trial has been submitted for publication.